A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sponsor: Solasia Pharma K.K.
Listed as NCT02653976, this PHASE2 trial focuses on Peripheral T-Cell Lymphoma and remains completed. Sponsored by Solasia Pharma K.K., it has been updated 14 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Sep 2021 — Feb 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Solasia Pharma K.K.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beitou, Taiwan , Chuo-ku, Japan , Fukuoka, Japan , Gangnam-gu, South Korea , Gifu, Japan , Goyang-si, South Korea , Hong Kong, Hong Kong , Hwasun-gun, South Korea , Isehara, Japan , Koto-ku, Japan and 14 more locations